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Acyl-CoA dehydrogenase (ACAD) defects in isoleucine and valine catabolism have been proposed in clinically
diverse patients with an abnormal pattern of metabolites in their urine, but they have not been proved enzymatically
or genetically, and it is unknown whether one or two ACADs are involved. We investigated a patient with isolated
2-methylbutyrylglycinuria, suggestive of a defect in isoleucine catabolism. Enzyme assay of the patient’s fibroblasts,
using 2-methylbutyryl-CoA as substrate, confirmed the defect. Sequence analysis of candidate ACADs revealed
heterozygosity for the common short-chain ACAD A625 variant allele and no mutations in ACAD-8 but a 100-
bp deletion in short/branched-chain ACAD (SBCAD) cDNA from the patient. Our identification of the SBCAD
gene structure (11 exons; 120 kb) enabled analysis of genomic DNA. This showed that the deletion was caused
by skipping of exon 10, because of homozygosity for a 1228GrA mutation in the patient. This mutation was not
present in 118 control chromosomes. In vitro transcription/translation experiments and overexpression in COS
cells confirmed the disease-causing nature of the mutant SBCAD protein and showed that ACAD-8 is an isobutyryl-
CoA dehydrogenase and that both wild-type proteins are imported into mitochondria and form tetramers. In
conclusion, we report the first mutation in the SBCAD gene, show that it results in an isolated defect in isoleucine
catabolism, and indicate that ACAD-8 is a mitochondrial enzyme that functions in valine catabolism.
Introduction
The individual role of the different acyl-CoA dehydro-
genases (ACADs) in isoleucine and valine catabolism
is at present unclear, and the underlying enzymatic de-
fects causing accumulation of metabolites derived from
isobutyryl-CoA and 2-methylbutyryl-CoA are poorly
understood. In 1994, a cDNA encoding a human ho-
mologue of rat 2-methyl–branched-chain ACAD was
cloned and characterized (Rozen et al. 1994). The
enzyme was named “short/branched-chain ACAD”
(SBCAD), because it differed from its rat homologue in
that it exhibited highest activity with butyryl-CoA and
2-methylbutyryl-CoA and low or no activity (Rozen et
al. 1994; Binzak et al. 1999) with isobutyryl-CoA, sug-
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gesting a primary role in isoleucine catabolism and, per-
haps, also in the catabolism of (short-chain) fatty acids,
but not in valine catabolism. So far, none of the ACADs
have been demonstrated to have significant enzyme ac-
tivity with isobutyryl-CoA as substrate. However, the
recently identified ACAD-8 (Telford et al. 1999), with
unknown substrate specificity, exhibits the highest de-
gree of sequence similarity to SBCAD and to short-chain
ACAD (SCAD). Therefore, it is a candidate enzyme for
branched-chain amino acid catabolism.
In the present study, we characterize the human
SBCAD gene structure and describe the identification
and characterization of the first mutation in the human
SBCAD gene from a patient with 2-methylbutyrylgly-
cinuria. Moreover, we investigate the mitochondrial im-
port, processing, and enzyme activities of overexpressed
human SBCAD and ACAD-8.
Patient and Methods
Case History
This 3-year-old boy is the second of three children of
a marriage between first cousins from Pakistan. Preg-
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nancy, delivery, and the neonatal period were without
complications. At age 3 mo, he was referred to the local
hospital, after 2 d of low caloric intake, because of a
feverish illness. During his 2d year of life, he became
increasingly floppy. He has since had retarded motor
development, generalized muscular atrophy, and stra-
bismus. At age 3 years he is able to walk with support.
Magnetic-resonance imaging was normal at age 2 years.
Urinary organic acid analysis revealed a consistent 2-
methylbutyrylglycinuria, with excretion of only trace
amounts of isobutyrylglycine. Plasma concentrations of
free and total carnitine were slightly below normal
ranges. Analysis of the newborn blood spot from the
patient showed a normal acylcarnitine profile, as mea-
sured by electrospray tandem mass spectrometry (Ra-
shed et al. 1995).
Both parents, a brother (age 12 mo), and a sister (age
4.5 years) of the patient have been without symptoms
of disease. However, analysis of the family members
showed that, in addition to the index case, the mother
also excreted 2-methylbutyrylglycine.
Extraction of Total RNA, Northern Blot Analysis, cDNA
Synthesis, PCR Amplification, and Sequence Analysis
of SBCAD and ACAD-8 cDNA
Extraction of total RNA from fibroblasts was per-
formed using an RNAzol kit (WAK-Chemie). Fifteen mi-
crograms total RNA was used for northern blot analysis
using a SBCAD cDNA (position 5 to 1374) hybridi-
zation probe. Blots were visualized on a Molecular Dy-
namics PhosphorImager. First-strand cDNA synthesis
was performed from total RNA using the first-strand
cDNA synthesis kit (Clontech). PCR amplification of the
entire coding region of SBCAD cDNA (position 5 to
1374) and ACAD-8 cDNA (position 44 to 1489) was
performed using standard conditions. The PCR products
were subjected to bidirectional cycle sequencing, using
a sequencing kit (BigDye terminator; PE Biosystems),
and analyzed on ABI 373A and ABI 377 sequencers (PE
Biosystems).
Identification of the Human SBCAD Gene Structure
and Sequence Analysis of the Patient’s Genomic DNA
tBLASTn searches of the GenBank database, with
the human SBCAD amino acid sequence, identified
the following bacterial artificial chromosomes
(BACs): AC012391, AQ306749, and AQ779739.
BAC AC012391 has been mapped to chromosome
10q25. BACs were obtained from The Sanger Centre
or Research Genetics, and DNA was prepared with a
Midi prep kit (Qiagen). Intron sizes were estimated
from agarose gel electrophoresis of PCR products am-
plified with exon-located primers. Regions of the
SBCAD gene not covered by the BACs were sequenced
from amplified genomic DNA from controls. All se-
quencing was performed with a combination of prim-
ers located in introns and exons of the SBCAD gene.
The resulting sequence information was used to design
primers (sequences are available on request) for am-
plification and sequence analysis of all exons and part
of the flanking introns. All exons of the SCAD gene
were amplified and sequenced using intron-located
primers designed on the basis of the gene structure
(Corydon et al. 1997). PCRs were carried out under
standard conditions in an automated thermal cycler
(Thermal cycler 480; PE Biosystems).
Expression of Wild-Type and Mutant SBCAD and
ACAD-8 in COS-7 Cells
Human ACAD-8 cDNA (position 44 to position
1489) was cloned between the HindIII and ApaI sites of
the expression vector pcDNA3.1 (InVitrogen), and
wild-type and patient SBCAD cDNA (position 5 to
position 1374, with or without the 100-bp deletion) was
inserted between the HindIII and XhoI sites of
pcDNA3.1; error-free clones were named “pACAD-8-
WT,” “pSBCAD-WT,” and “pSBCAD-MUT,” respec-
tively. Transfection of COS-7 cells was performed using
FuGene 6 (Boehringer Mannheim), and cells were har-
vested 48 h posttransfection.
The activity of the overexpressed SBCAD and ACAD-
8 proteins was measured in cleared cell lysates, in a stan-
dard reaction medium (100 mM Tris, pH 8, and 100
mM flavin adenine dinucleotide) supplemented with 0.2
mM of either (S)-2-methylbutyryl-CoA, isobutyryl-CoA,
butyryl-CoA, or isovaleryl-CoA, with ferricenium as the
electron acceptor. The formation of tiglyl-CoA and 2-
methyl-3-hydroxybutyryl-CoA (from 2-methylbutyryl-
CoA), either methacrylyl-CoA and 2-methyl-3-hydrox-
ypropionyl-CoA (from isobutyryl-CoA) or butenoyl-
CoA and 3-hydroxy butyryl-CoA (from butyryl-CoA),
and 3-methyl-crotonyl-CoA and 3-hydroxy-isovaleryl-
CoA (from isovaleryl-CoA) was quantified using high-
performance liquid chromatography (HPLC) (C18 re-
versed phase, mm, methanol gradient, de-250# 10
tection at 263 nm). Isobutyryl-CoA, butyryl-CoA, and
isovaleryl-CoA (Sigma) and (S)-2-methylbutyryl-CoA
(synthesized by either the authors or by Jerry Vockley
[Mayo Clinic]) were used as substrates. Transfections
were performed at least twice, and enzyme activity was
measured in duplicate.
In Vitro Mitochondrial Import and Stability of Wild-
Type ACAD-8, Wild-Type SCAD, and Wild-Type and
Mutant SBCAD
In vitro transcription and translation was carried out
using the TnT coupled transcription/translation kit,
[35S]-methionine, and plasmids pSBCAD-WT, pSBCAD-
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Figure 1 A, PCR of SBCAD cDNA from the index patient (lane P1) and a normal control (lane C1), using a sense primer located in
exon 6 and an antisense primer located in exon 11. “P2” and “C2” result from identical amplifications as P1 and C1, respectively, except that
another sense primer, located in exon 8, was used. A blank amplification is marked by “Bl.” The size marker is indicated by “SM.” B, Agarose
gel electrophoresis after restriction digestion of PCR products from genomic DNA from the index patient (lane P), his mother (lane M), his
father (lane F), his healthy sister (lane S), his healthy brother (lane B), and a normal control (lane C), using a modified sense primer (5′-
ATTACCCTGTGGAGAAATACTGAGATGCAAAGACT-3′) located in exon 10 of the SBCAD gene and an antisense primer (5′-AAATCCA-
GCCACATAACTAGTGCCACCAAACATATACTG-3′) located in intron 10. Undigested PCR products (U) are 187 bp long. After digestion with
the SpeI restriction enzyme, PCR products harboring the 1228GrA mutation are 130 bp long, and PCR products with the wild-type sequence
are 167 bp. C, Two different northern blot analyses of 15 mg total fibroblast RNA from the patient (lane P) and a control (lane C), using a
SBCAD cDNA probe.
MUT, pSCAD-WT, and pACAD-8-WT, according to the
manufacturer’s protocol (Promega). The pSCAD-WT
plasmid was constructed by subcloning the coding re-
gion of human SCAD from pMP6 harboring SCAD
cDNA (Corydon et al. 1998) into the polylinker of
pcDNA3.1. Mitochondria were isolated from rat liver,
as described elsewhere (Gregersen 1979). The stability
and import of the translation products into mitochon-
dria were assayed essentially as described by Volchen-
boum and Vockley (2000). After SDS-PAGE and Native
PAGE (ReadyGels; BioRad), radioactive bands were vi-
sualized on a Molecular Dynamics PhosphorImager and
were quantified using Imagequant software (Molecular
Dynamics).
An ACAD-8 antibody was raised, in rabbits, against
a recombinant his-tag fusion protein of human ACAD-
8 (amino acids 1–415) expressed in Escherichia coli. In
situ immunostaining, localization, and confocal laser
scanning–microscopy analysis of ACAD-8 in transfected
COS-7 cells was performed as described elsewhere (Cor-
ydon et al. 1998).
Results
Identification of Acyl-CoA Dehydrogenase Deficiency
Organic acid analysis of the patient’s urine consis-
tently demonstrated the presence of 2-methylbutyryl-gly-
cine, suggesting an ACAD defect in the isoleucine path-
way. To evaluate this possibility, we set up an assay to
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Table 1
Exon-Intron Organization of the Human SBCAD Gene





Position 3′ Exon Sequence
Intron 5′
Splice Site Intron Size
.......... 1a CAGCAGGCTG gtgagtgcgt ???
ttccctacag 2 CTAAGAAGAA 160 43 AAGAGTTCAG gtaagtaaat ≈2.7 kb
ctgcccacag 3 TTAAAAAATT 101 203 TCAACAAGGG gtacagttca ≈2.3 kb
ttttctttag 4 TTGATGGGTA 207 304 TACAGAAAAA gtgagttgag ≈0.4 kb
ccatatgtag 5 GTAGGAAGTT 171 511 CCCTACCATT gtaagtttga ≈1.4 kb
ttctttttag 6 GGATATAAGG 126 682 AAATGTCAAG gtgggtatcg ≈1.0 kb
gtattttcag 7 GTTCCAGAAG 93 808 TGCTGCACAG gtaagtcaga ≈2.8 kb
gttttttcag 8 ATGCTGGGAC 90 901 TGATTTTCAG gtatgtaatt ≈6.5 kb
actgttacag 9 GGCCTCCAAC 138 991 TGCATCAGAG gtaaaaaaaa 1,874 bp
cttttggtag 10 ATTGCAGGAC 100 1129 GCAAAGATTG gtaaatagat 534 bp
tttgcttaagb 11 GTACGATATA ??? 1229
Consensus (yyyyyyynag) G......... .......AAG gtragt....
NOTE.—Start position of each exon is indicated relative to the corresponding position in the cDNA sequence; intron and
exon sizes are indicated, as well as 10 bp of the exon sequence and 10 bp of the intron sequence at each junction. The position
of the 1228GrA mutation observed in the patient is indicated by underlining. The sequence data have been submitted to the
GenBank database (accession numbers AF260668–AF260678).
a Transcription initiation site not determined.
b Poly A addition sites at cDNA positions 1388–92, 1916–20, and 2646–51.
determine the ACAD activity toward 2-methylbutyryl-
CoA in fibroblasts. HPLC was used to separate and
quantify the substrate and the reaction products from
lysed cells, using ferricenium as an electron acceptor.
The enzyme activity in the patient’s fibroblasts when 2-
methylbutyryl-CoA was used as substrate was shown to
be decreased to 10% of controls (control, 0.157 nmol/
min/mg protein; patient, 0.016 nmol/min/mg protein
[10%]).
Sequence Analysis
We decided to analyze the cDNA sequence of the
ACAD-8 and SBCAD genes from our patient and from
two controls, to see whether the excreted 2-methylbutyr-
ylglycine and the deficient enzyme activity with 2-meth-
ylbutyryl-CoA as substrate could be caused by a defect
in one or both of these enzymes. Moreover, because pa-
tients with SCAD deficiency may have small amounts of
2-methylbutyrylglycine in their urine (Tein et al. 1999),
we also amplified and sequenced all exons of our patient’s
SCAD gene. The patient was found to be heterozygous
for the A625 polymorphism (Corydon et al. 1996). No
other changes were identified. PCR amplification and se-
quencing of the ACAD-8 protein–coding region from
cDNA revealed no differences from the published se-
quence (Telford et al. 1999), either in our patient or in
the two controls. Interestingly, two of the PCR products,
produced with two different SBCAD sense primers and a
common SBCAD antisense primer, were ∼100 bp shorter
when amplified from the patient’s cDNA than when am-
plified from control cDNA (fig. 1A). Sequence analysis
revealed a 100-bp deletion of cDNA positions 1129–1228
in the patient. SBCAD mRNA with this deletion has a
shifted reading frame after glutamate 376 and a prema-
ture stop codon 12 codons downstream. In addition, the
patient and one of the controls were homozygous for the
silent mutations 351TrA and 639TrC. The second con-
trol was homozygous for 351TrA and heterozygous for
639TrC. A tBLASTn search of the human expressed-
sequence-tag database at GenBank indicated that these
are normal sequence variations. No other changes in the
coding region of SBCAD cDNA were observed in either
the patient or the controls.
Identification of the SBCAD Gene Structure and
Investigation of Genomic DNA from the Patient, His
Family Members, and a Control
To investigate the molecular basis for the deletion, we
identified and characterized the genomic structure of the
human SBCAD gene (accession numbers AF260668–
AF260678) (see Patient and Methods section). The
SBCAD gene structure (table 1) was confirmed by PCR
and by direct sequencing of all exons from genomic
DNA from a control.
PCR amplification and sequence analysis of genomic
DNA from a control and from the patient showed
that the 100-bp sequence deleted in the patient’s cDNA
was present in his genomic DNA, excluding a genomic
deletion. The deleted sequence corresponds to exon 10
(table 1), indicating that aberrant splicing of SBCAD
mRNA causes the deletion. Sequence analysis of am-
plified genomic DNA showed that the patient was ap-
parently homozygous for a single GrA transition
(1228GrA) in exon 10. Amplification of genomic DNA
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Figure 2 Position, in the SBCAD gene, of the 1228GrA mu-
tation, and the resulting aberrant splicing in the patient, compared
with the normal splicing pattern in a control person. The position of
the 1228GrA mutation observed in the patient is indicated by boldface
italic type.
with primers that introduced a SpeI restriction site only
in mutant DNA, followed by digestion with SpeI (fig.
1B), showed homozygosity for the 1228GrA mutation
in the patient and heterozygosity in the father and in
both healthy siblings (fig. 1B). Interestingly, the mother
was also found to be homozygous for the mutation. This
was confirmed by sequence analysis of a PCR product
from the mother that harbored exon 10. Analysis of the
family members showed that, just like the patient, the
mother excretes 2-methylbutyrylglycine in her urine. The
1228GrA mutation changes the codon for glycine 410
to that for serine and is located at the last nucleotide in
the skipped exon 10 (table 1 and fig. 2). Sequence anal-
ysis of both introns flanking exon 10, in both a control
and the patient, revealed no other changes in the splice
consensus sequences. Therefore, we believe that the
1228GrA mutation causes the observed skipping of
exon 10 in the patient’s SBCAD mRNA. Analysis by
PCR amplification of two different cDNAs from the pa-
tient, using different sense and antisense primers located
in different exons flanking the skipped exon, indicated
that no normal-sized SBCAD mRNA is detectable (fig.
1A and not shown) and thus that the 1228GrA mu-
tation affects splicing severely. Northern blot analysis of
two different preparations of total RNA, from the pa-
tient’s and from control fibroblasts, showed that the
steady-state amounts of SBCAD mRNA are comparable
(fig. 1C). Sequence analysis of exon 10 amplified from
genomic DNA from 59 Danish controls (118 alleles)
showed that the 1228GrA mutation was not present.
Expression of Wild-Type and Mutant SBCAD, ACAD-8,
and SCAD in COS-7 Cells
To demonstrate the disease-causing nature of the
1228GrA mutation, we analyzed both the mutant
SBCAD protein encoded by the mRNA resulting from
exon skipping and the wild-type SBCAD protein result-
ing from overexpression. In addition, we overexpressed
wild-type human ACAD-8, with the purpose of com-
paring the substrate specificity to that of SBCAD. Our
results showed that mutant SBCAD protein has no en-
zyme activity and that the substrate for SBCAD wild-
type protein is 2-methylbutyryl-CoA (fig. 3). Further-
more, our results showed that the main substrate for
ACAD-8 is isobutyryl-CoA but that it also has activity
with 2-methylbutyryl-CoA. None of the enzymes had
significant activity toward either butyryl-CoA or iso-
valeryl-CoA.
In Vitro Mitochondrial Import and Stability of Wild-
Type and Mutant SBCAD, ACAD-8, and SCAD
To further study the molecular defect of the mutant
SBCAD protein and to investigate whether precursor
SBCAD, SCAD, and ACAD-8 proteins are imported in-
to mitochondria and are correctly processed, we used a
coupled in vitro transcription/translation system to syn-
thesize radioactively labeled precursor proteins and in-
cubated them with isolated rat mitochondria. Our anal-
ysis by SDS-PAGE showed that both mutant and
wild-type precursor SBCAD protein, precursor wild-type
ACAD-8, and precursor wild-type SCAD proteins were
imported into mitochondria and were processed to ma-
ture size (fig. 4A and C). The stability of the imported
proteins was investigated by testing samples withdrawn
at different time points, after removal of all unimported
precursor proteins by trypsin digestion and washing.
This indicated that mutant SBCAD protein decayed
slightly faster than wild-type SBCAD (fig. 4A). Investi-
gation of the imported proteins by native PAGE showed
that wild-type SBCAD, SCAD, and ACAD-8 proteins
formed larger complexes inside the mitochondria, cor-
responding in size to tetramers, and that mutant SBCAD
protein failed to do so (fig. 4B). Furthermore, a high-
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Figure 3 Enzyme activities after expression of wild-type and mutant SBCAD and ACAD-8 in COS-7 cells. The results from measuring
ACAD activity in COS-7 cells transfected with pSBCAD-WT, pSBCAD-MUT, or pACAD-8-WT expression vectors are shown. The control is
COS-7 cells harboring the expression vector pcDNA3.1 with no cDNA insert (Control). Activity measurements are given in nmol/min/mg
protein. Blackened bars show the enzyme activity measured with 2-methylbutyryl-CoA as substrate, and gray bars show the enzyme activity
measured with isobutyryl-CoA as substrate. Error bars indicate the range of the values measured. None of the transfected cells showed activity
above background when either butyryl-CoA or isovaleryl-CoA was used as substrate (not shown).
molecular-weight band shown, by Western blot anal-
ysis (authors’ unpublished results), to comigrate with
mHsp60, was much more prominent in extracts from
cells overexpressing mutant SBCAD protein than in ex-
tract from cells overexpressing wild-type SBCAD.
These results may indicate that the mutant SBCAD
protein is unable to form tetramers and, instead, remains
in complex with chaperones, such as mHsp60, a ten-
dency previously observed with mutant medium-chain
ACAD (MCAD) (Saijo et al. 1994; Andresen et al. 1997;
Bross et al. 1998).
Finally, we analyzed intact COS-7 cells overexpressing
ACAD-8, using in situ immunostaining (see Patient and
Methods section). Using our anti–ACAD-8 antibody to-
gether with a monoclonal anti-mitochondrial Hsp60 an-
tibody, followed by confocal laser scanning–microscopy
analysis, we could demonstrate that ACAD-8 and en-
dogenous mHsp60 colocalize (results not shown).
Discussion
The number and the individual role of the candidate en-
zymes for the ACAD step in the catabolism of isoleucine
and valine are still not elucidated, and neither genetic nor
enzymatic evidence for inherited defects has so far been
reported. In the present study, we show, using 2-meth-
ylbutyryl-CoA as enzyme substrate, severely decreased en-
zyme activity in the fibroblasts from a patient with 2-
methylbutyrylgycinuria. This demonstrates, for the first
time, the existence of an ACAD defect in isoleucine me-
tabolism. Consequently, we initiated a molecular genetic
characterization of the candidate genes, SBCAD, ACAD-
8, and SCAD, from our patient. We found that he had
no changes in the ACAD-8 gene and was only hetero-
zygous for the SCAD A625 variant. Instead, the enzymatic
defect could be explained by our finding that he is ho-
mozygous for a 1228GrA mutation that changes the co-
don for glycine 410 to serine in the SBCAD gene. It is,
however, obvious that the deleterious effect of the mu-
tation does not result from this amino acid change, since
the mutation results in complete skipping of the consti-
tutive exon (fig. 2). Mutations (such as 1228GrA) of the
consensus G at the1 position of the 5′ splice site usually
result in exon skipping, and GrA is observed in two-
thirds of all such mutations (Nakai and Sakamoto 1994).
Our analysis of the patient’s cDNA shows that no normal
splicing occurs (fig. 1A). It is not obvious why this
1GrA change has such a drastic effect. At first glance,
this 5′ splice site of the human SBCAD gene (table 1)
conforms well with human splice consensus sequences
(Zhang 1998). However, the sequence of the last three
nucleotides of SBCAD exon 10 is TTG, which is much
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Figure 4 In vitro mitochondrial import and stability of wild-type and mutant SBCAD, wild-type ACAD-8, and wild-type SCAD. Wild-
type and mutant SBCAD, wild-type ACAD-8, and SCAD wild-type precursor proteins were synthesized by coupled in vitro transcription/
translation and were incubated with isolated rat mitochondria for 30 min. After removal, by washing, of unimported precursor proteins, the
fate of the imported proteins was followed for different time intervals. Twenty-microliter samples of the mitochondria were collected at the
time points indicated, were washed two times, and were incubated with trypsin, followed by addition of trypsin inhibitor. Then samples were
lysed and subjected to centrifugation. Finally, the supernatant fraction was subjected to either SDS-PAGE (A and C) or native PAGE (B). A 1-
ml sample of the total translatate (Tt) withdrawn prior to incubation with mitochondria was also subjected to electrophoresis. The positions
and molecular masses of coelectrophoresed marker proteins are indicated on the left margin. Positions of the precursor (P) and the mature (M)
form of the respective proteins are shown on the right margin, and the position corresponding to the tetrameric proteins (T) and mHsp60
chaperone complexes (C) are indicated. The positions of the chaperone complexes were demonstrated by western blot analysis using an anti-
mHsp60 antibody (authors’ unpublished results). In the total translatate produced from the pACAD-8-WT plasmid, a lower-molecular-weight
band (denoted by the asterisk [*]) was present, but the corresponding polypeptides were not imported into mitochondria. We presume that this
band represents ACAD-8 proteins in which an internal in-frame ATG codon has been used as the translation start signal. Such internal ATGs,
which are present in a more optimal sequence context for translation initiation (Kozak 1989) than are the correct ATG, are located at positions
115–117 and 178–180 in the ACAD-8 cDNA. Initiation of translation at either of these positions will result in production of proteins without
a mitochondrial targeting sequence and with a size corresponding to the lower-molecular-weight band.
less frequently observed than the consensus, AAG (Zhang
1998). This could perhaps be of importance, since it has
been demonstrated that, with smaller-than-average-size
exons (such as SBCAD exon 10), the requirement for a
consensus splice sequence is more stringent (Zhang 1998).
SBCAD mRNA with the 100-bp deletion encodes a
protein in which the reading frame is shifted after glu-
tamate 376, ending with a premature translation ter-
mination codon (PTC) 12 codons downstream (fig. 2).
This PTC is located in the last exon of the SBCAD gene,
which explains why we observe normal amounts of mu-
tant SBCAD mRNA, despite the fact that introduction
of a PTC will usually result in low steady-state amounts
of mRNA (Maquat 1995). Evidence from several genes
shows that a PTC has to be located 150–55 nucleotides
upstream of the most 3′ exon-exon junction to have an
effect (Nagy and Maquat 1998).
Because the mutant mRNA is stable, it is likely that
the encoded mutant protein is produced. It is, however,
very unlikely that this mutant protein has any enzyme
activity, since several functionally important amino acids,
such as the active-site glutamate 414 (Binzak et al. 1998),
are missing. Moreover, overexpression of wild-type and
mutant SBCAD protein in COS-7 cells and in vitro tran-
scription/translation experiments have shown that the
mutant protein has no detectable enzyme activity (fig. 3)
and that it has a slightly reduced stability and a lack of
ability to form tetramers (fig. 4). This is consistent with
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previous observations from characterization of two dis-
ease-causing PTC mutations (R324X and E359X) in
MCAD (Andresen et al. 1994) and by recent experiments,
with mutant isovaleryl-CoA dehydrogenase proteins
(Volchenboum and Vockley 2000), that show that the
carboxy-terminal part of an ACAD is necessary for sub-
unit interaction and tetramer stability.
Together with our finding that the mutation was not
present in 118 control chromosomes, these results
clearly demonstrate that the 1228GrA mutation is del-
eterious. We therefore conclude that the enzyme defect
in our patient is caused by homozygosity for the SBCAD
1228GrA mutation.
The fact that isolated accumulation of 2-methylbu-
tyrylglycine with only trace amounts of isobutyrylgly-
cine was observed in our patient, together with the fact
that human SBCAD has no detectable activity with iso-
butyryl-CoA indicates that, in humans, SBCAD defi-
ciency affects isoleucine catabolism and not valine ca-
tabolism. It is therefore obvious that another ACAD
serves the valine pathway. A likely candidate for this is
ACAD-8, since we have shown in the present study that
this enzyme has very high activity toward isobutyryl-
CoA.
Recently, another patient, who showed a metabolite
pattern (2-methylbutyrylcarnitine and 2-methylbutyr-
ylglycine in body fluids) similar to that of our patient
was reported (Gibson et al. 1999). The initial clinical
presentation of this patient (presentation, at day 3 of
life, with hypoglycemia, lethargy, and apnea) was
different from that observed in our patient, although
both have developed neurological symptoms. This in-
dicates that patients with SBCAD deficiency may pre-
sent differently. Such clinical heterogeneity is common
in ACAD defects (Andresen et al. 1997, 1999). Like-
wise, the finding that the clinically asymptomatic
mother has a genotype identical to that of the index
patient and that she excretes 2-methylbutyrylglycine in
her urine is not so surprising; it may illustrate the emerg-
ing fact that the mere presence of the genetic defect is
not always enough to cause clinical disease in inherited
metabolic disorders. We have previously observed the
same phenomenon in families suffering from other
ACAD defects, such as MCAD and glutaryl-CoA de-
hydrogenase deficiency, in which asymptomatic genet-
ically affected siblings and parents of a clinically af-
fected patients have been identified (Amir et al. 1989;
Andresen et al. 1997). The finding that the clinical man-
ifestation of SBCAD deficiency in our patient was pre-
ceded by episodes of infectious disease further corrob-
orates our notion (Andresen et al. 1997) that
environmental factors, such as metabolic stress and fe-
ver, may be crucial determinants of the clinical phe-
notype in genetically affected individuals. An explana-
tion for this could be that overlapping enzyme activity
from ACAD-8 and SCAD is sufficient to avoid harmful
accumulation of metabolites from isoleucine metabo-
lism in patients with SBCAD deficiency when they are
not subjected to metabolic stress.
Note added in proof.—After submission of this man-
uscript, a paper describing heterozygosity for a mutation
SBCAD cDNA in a patient with 2-methylbutyrylglycin-
uria was reported by Gibson et al. (2000).
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